ライフサイエンスコーパス: HIV protease inhibitor

1 on glucose transport were observed for other HIV protease inhibitors.

2 d the urgent need for a second generation of HIV protease inhibitors.

3 (3)-P(2) position of hydroxyethylamine-based HIV protease inhibitors.

4 al protease increase the binding affinity of HIV protease inhibitors.

5 of HIV with resistance to a wide variety of HIV protease inhibitors.

6 now being used and the more frequent use of HIV protease inhibitors.

7 useful for designing specific and efficient HIV protease inhibitors.

8 10 pi-aromatic system of Ro 31-8959 class of HIV protease inhibitors.

9 roviral drugs, such as efavirenz and boosted HIV protease inhibitors.

10 Compound 2a is a key intermediate toward HIV protease inhibitors.

11 ituent effects to the analysis and design of HIV protease inhibitors.

12 of epi-aortic lesions in patients receiving HIV protease inhibitors.

13 ease in HIV-1 infected patients treated with HIV protease inhibitors.

14 atives could have potential use as effective HIV protease inhibitors.

15 fragment to fill S1' and S2' afforded potent HIV protease inhibitor 49 [IC50 = 10 nM, 3-[(2-tert-buty

16 are amino alcohol 1, the core portion of the HIV protease inhibitor A-792611, in 46% yield from pheny

17 an immunodeficiency virus (HIV) treated with HIV protease inhibitors, a complication develops that re

18 HIV protease inhibitors acutely block glucose transporte

19 iseases like atherosclerosis it appears that HIV protease inhibitors affect the cardiovascular system

20 The HIV protease inhibitor amprenavir inhibits calpain activ

21 ed that peptidomimetic FISLE-412,1 a reduced HIV protease inhibitor analogue, was well-tolerated, alt

22 We also resolved binding of zinc, lipids and HIV protease inhibitors and showed that drug binding blo

23 poor pharmacokinetic properties of existing HIV protease inhibitors and, potentially, other drug cla

24 Ritonavir is a human immunodeficiency virus (HIV) protease inhibitor and an inhibitor of cytochrome P

25 with three probes (a thrombin inhibitor, an HIV protease inhibitor, and a model for angiotensin II).

26 HIV protease inhibitors are a key component of anti-retr

27 ation of a series of nonpeptidic macrocyclic HIV protease inhibitors are described.

28 tructure-based design and synthesis of novel HIV protease inhibitors are described.

29 nd synthesis of a series of novel nonpeptide HIV protease inhibitors are described.

30 Interestingly, HIV protease inhibitors are distinct from previously kno

31 HIV protease inhibitors are thus a new class of anticanc

32 (RTV)-boosted human immunodeficiency virus (HIV) protease inhibitors are coadministered in healthy v

33 We conclude that HIV protease inhibitors as a class are capable of select

34 or the discovery of more potent non-peptidic HIV protease inhibitors as potential therapeutic agents

35 poorly soluble human immunodeficiency virus (HIV) protease inhibitor based upon in vivo test results.

36 . 2c) were identified as potent, nonpeptidic HIV protease inhibitors, but these compounds lacked sign

37 e made the intriguing discovery that several HIV-protease inhibitors can function as decoy antigens t

38 The HIV protease inhibitor class of antiretroviral drug caus

39 f lopinavir, a human immunodeficiency virus (HIV) protease inhibitor, coformulated with ritonavir as

40 Crystallographic studies of HIV protease-inhibitor complexes help explain the perhap

41 inhibitors, utilizing crystal structures of HIV protease/inhibitor complexes, provided a rational ba

42 Computational modeling revealed that HIV-protease inhibitors comprised structural features pr

43 of (2R)-indandiol, a chiral precursor of the HIV protease inhibitor, Crixivan.

44 we tested the hypothesis that indinavir, an HIV-protease inhibitor, directly induces insulin resista

45 s an illustration, the core structure of the HIV protease inhibitors DMP 323 and DMP 450 has been pre

46 ding lupus medications, thrombin inhibitors, HIV protease inhibitors, DNA gyrase inhibitors and many

47 or the progeria-like side effects of certain HIV protease inhibitor drugs, but also highlight new app

48 ination antiretroviral therapy that includes HIV protease inhibitors experience atrophy of peripheral

49 ed the safety and efficacy of saquinavir, an HIV-protease inhibitor, given with one or two nucleoside

50 d rapid biliary excretion of peptide-derived HIV protease inhibitors have limited their utility as po

51 Human immunodeficiency virus (HIV) protease inhibitors have been successfully used in

52 HIV protease inhibitors (HIV PI) are a class of antiretr

53 HIV protease inhibitors (HIV-PIs) are key components of

54 HIV protease inhibitors (HIV-PIs) target the HIV asparty

55 Inhibitors of the HIV aspartyl protease [HIV protease inhibitors (HIV-PIs)] are the cornerstone o

56 Human immunodeficiency virus (HIV) protease inhibitors (HIV PIs) are the core componen

57 The HIV protease inhibitors (HPI) amprenavir, nelfinavir, an

58 and diabetes are recognized side effects of HIV protease inhibitors (HPIs), suggesting that these ag

59 he present study, we examined the effects of HIV protease inhibitors in female LDL-R null mice.

60 cal approaches used to determine the role of HIV protease inhibitors in the development of cardiovasc

61 trials have established the critical role of HIV protease inhibitors in the treatment of acquired imm

62 fectiveness of human immunodeficiency virus (HIV) protease inhibitors in acquired immunodeficiency sy

63 of non-peptide human immunodeficiency virus (HIV) protease inhibitors in short analysis time and auto

64 block for several clinical and experimental HIV protease inhibitors including the highly important d

65 ause for the loss of sensitivity toward many HIV protease inhibitors, including our first-generation

66 ease, monofluorinated analogues of the Merck HIV protease inhibitor indinavir, are described.

67 We demonstrate that the HIV protease inhibitor, indinavir, dramatically inhibits

68 sity lipoprotein receptor (LDL-R) null mice, HIV protease inhibitors induce atherosclerotic lesions a

69 t role in the gender differences observed in HIV protease inhibitor-induced atherosclerosis.

70 er, the cellular/molecular mechanisms of the HIV protease inhibitor-induced lipid dysregulation and a

71 chemotherapeutic agents, antipsychotics, and HIV protease inhibitors, into and out of the central ner

72 The clinical use of HIV protease inhibitors is associated with insulin resis

73 Treatment of patients infected with HIV with HIV protease inhibitors is unfortunately associated with

74 In vitro and in vivo data suggest that the HIV protease inhibitors lopinavir/ritonavir may have pot

75 Poor adherence to HIV protease inhibitors may compromise the effectiveness

76 iscuss possible molecular mechanisms whereby HIV protease inhibitors may promote atherogenesis.

77 In conclusion, HIV protease inhibitors may, by blocking the caspase-dep

78 Notably, Indinavir; an HIV protease inhibitor, may be effective in reducing the

79 rrently available data strongly suggest that HIV protease inhibitors negatively impact the cardiovasc

80 We investigated the effects of HIV protease inhibitors on adipogenesis and adipocyte su

81 on mass spectrometry to study the effects of HIV protease inhibitors on the human zinc metalloproteas

82 sed in vitro and in vivo models to show that HIV protease inhibitor (PI) class ARVs induced neuronal

83 GS-8374 is a potent HIV protease inhibitor (PI) with a unique diethyl-phosph

84 an allophenylnorstatine-containing dipeptide HIV protease inhibitor (PI), which is potent against a w

85 s a once-daily human immunodeficiency virus (HIV) protease inhibitor (PI) shown to be effective and w

86 a nonpeptidic human immunodeficiency virus (HIV) protease inhibitor (PI), containing 3(R),3a(S),6a(R

87 Human immunodeficiency virus (HIV) protease inhibitor (PI)-induced adverse effects hav

88 HIV protease inhibitors (PIs) acutely and reversibly inh

89 First-generation HIV protease inhibitors (PIs) alter proteasome activity,

90 Pharmacologic HIV protease inhibitors (PIs) and structurally related o

91 While drugs like HIV protease inhibitors (PIs) and trimethoprim-sulfameth

92 HIV protease inhibitors (PIs) avert apoptosis in part by

93 The use of HIV protease inhibitors (PIs) has been associated with s

94 , and oral administration of prodrugs of the HIV protease inhibitors (PIs) lopinavir and ritonavir.

95 This study examined the effects of HIV protease inhibitors (PIs) on bone resorption, bone f

96 In this article, we show that HIV protease inhibitors (PIs) prescribed to HIV-infected

97 tiretroviral therapy (HAART), which includes HIV protease inhibitors (PIs), has been associated with

98 drug classes such as nucleoside analogs and HIV protease inhibitors (PIs), has increased HIV-patient

99 , which appears to be exacerbated by certain HIV protease inhibitors (PIs).

100 Human immunodeficiency virus (HIV) protease inhibitors (PIs) act as reversible noncomp

101 onstrated that human immunodeficiency virus (HIV) protease inhibitors (PIs) exert inhibitory effects

102 Human immunodeficiency virus (HIV) protease inhibitors (PIs) have been used successful

103 Human immunodeficiency virus (HIV) protease inhibitors (PIs) recently have been report

104 efficacy of 5 human immunodeficiency virus (HIV) protease inhibitors (PIs) was examined by the effec

105 d screening program to discover non-peptidic HIV protease inhibitors previously identified compound I

106 rovide possible cellular mechanisms by which HIV protease inhibitors promote atherosclerosis and card

107 Preclinically, HIV protease inhibitors radiosensitize tumors with activ

108 lues for inhibition of HIV-1 protease by the HIV protease inhibitors ranged from 0.24 nM to 1.0 micro

109 esistant HIV strains, the development of new HIV protease inhibitors remains a high priority for the

110 The design of new HIV protease inhibitors requires an improved understandi

111 anti-retroviral therapies, which incorporate HIV protease inhibitors, resolve many AIDS-defining illn

112 ing to the potent and clinically efficacious HIV protease inhibitor ritonavir are described.

113 or inhibition of glucose transport with the HIV protease inhibitor ritonavir elicited growth arrest

114 lines and primary cells by the FDA-approved HIV protease inhibitor ritonavir, which exerts a selecti

115 The HIV protease inhibitor ritonavir, which inhibits calpain

116 trate that the human immunodeficiency virus (HIV) protease inhibitor ritonavir binds SXR and activate

117 s study, we demonstrate that three different HIV protease inhibitors (ritonavir, indinavir, and ataza

118 daily 10 mg/kg intraperitoneal injection of HIV protease inhibitors (ritonavir, lopinavir/ritonavir

119 The molecular mechanisms of action of a HIV protease inhibitor, ritonavir, on hepatic function w

120 Ritonavir is a HIV protease inhibitor routinely prescribed to HIV patie

121 inal tyrosine peptide aldehydes based on the HIV protease inhibitors (S)-MAPI and GE 20372 A.

122 Finally, the HIV protease inhibitors saquinavir and ritonavir were po

123 cess an important synthetic precursor to the HIV-protease inhibitor, saquinavir, by formation of an N

124 enzyl P1/P1' moiety of the cyclic urea based HIV protease inhibitor series.

125 Human immunodeficiency virus (HIV) protease inhibitors show activity against Plasmodiu

126 uct FK506, we have synthetically modified an HIV protease inhibitor such that it acquires high affini

127 several potent human immunodeficiency virus (HIV) protease inhibitors such as LY289612.

128 patients with human immunodeficiency virus (HIV) protease inhibitors such as ritonavir can result in

129 chiral building blocks for the synthesis of HIV protease inhibitors, such as atazanavir and darunavi

130 Antiretroviral regimens containing HIV protease inhibitors suppress viremia in HIV-infected

131 We examined the effect of nelfinavir, an HIV protease inhibitor that inhibits Akt signaling, on V

132 , in the presence of dilated cardiomyopathy, HIV protease inhibitors that impair glucose transport in

133 anism by which human immunodeficiency virus (HIV) protease inhibitor therapy adversely induces lipody

134 The potential for HIV protease inhibitors to contribute to or exacerbate c

135 hat it is an important regulator involved in HIV protease inhibitor toxicity and host-microbial patho

136 uran, a high-affinity nonpeptidal ligand for HIV protease inhibitor UIC-94017, is described.

137 A series of symmetry-based HIV protease inhibitors was designed and synthesized.

138 ivity of three human immunodeficiency virus (HIV) protease inhibitors was investigated in human prima

139 a Merck compound synthesized as a potential HIV protease inhibitor, was investigated using recombina

140 Starting from palinavir (1), our lead HIV protease inhibitor, we have discovered a new series

141 HIV protease inhibitors were developed in the early 1990

142 Several HIV protease inhibitors were found either to inhibit pre

143 rapeutic concentrations (5-15 microM), these HIV protease inhibitors were found to increase the level

144 type 2 diabetes mellitus, and nelfinavir, an HIV protease inhibitor, when used alone or in combinatio

145 d from S-aryl-D-cysteine proved to be potent HIV protease inhibitors which also exhibited potent whol

146 e (HAPA) transition-state isostere series of HIV protease inhibitors, which initially resulted in the

147 d UIC-94017 (TMC-114) is a second-generation HIV protease inhibitor with improved pharmacokinetics th

148 ided an example of a promising new series of HIV protease inhibitors with significantly improved enzy

149 mprenavir is a human immunodeficiency virus (HIV) protease inhibitor with a favorable pharmacokinetic

150 template provided a series of highly potent HIV protease inhibitors, with structure-activity relatio

151 le resistance at entry became susceptible to HIV-protease inhibitors within 16 weeks after the discon